Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glimepiride + curcumin
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of glimepiride, an antidiabetic medication from the sulfonylurea class, and curcumin, a natural compound found in turmeric. Laboratory studies have shown that co-administration of curcumin and glimepiride resulted in a 57.5% reduction in blood glucose levels after 28 days compared to 51.2% with glimepiride alone and 46.8% with curcumin alone in diabetic rats, suggesting a synergistic effect. This combination may offer improved glycemic control and potential benefits in preventing diabetes-related complications.
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)KCNJ11 (Atp-sensitive inward rectifier potassium channel 11)NF-κBKATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on glimepiride + curcumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glimepiride + curcumin.